Table of Contents

State/Territory: Indiana

State Plan Amendment (SPA)#: 20-014

This file contains the following documents in the order listed:

1) Approval Letter
2) CMS 179 Form
3) Approved SPA Pages
Center for Medicaid and CHIP Services

Disabled and Elderly Health Programs Group

September 28, 2020

Ms. Allison Taylor
Medicaid Director
Indiana Office of Medicaid Policy and Planning
402 W Washington St Rm W382
Indianapolis, IN 46204-2776

Dear Ms. Taylor:

The CMS Division of Pharmacy team has reviewed Indiana State Plan Amendment (SPA) 20-0014 received in the Division of Program Operations North Branch on September 1, 2020. This SPA proposes to make technical changes to the template utilized in administering the State’s supplemental drug rebate program.

Based on the information provided and consistent with the regulations at 42 CFR 430.20, we are pleased to inform you that SPA 20-0014 is approved with an effective date of September 1, 2020. A copy of the updated signed CMS-179 form, as well as the pages approved for incorporation into Indiana’s state plan will be forwarded by the Division of Program Operations North Branch.

If you have any questions regarding this request, please contact Justin Aplin at (410) 786-6901 or Justin.Aplin@cms.hhs.gov.

Sincerely,

/s/

Cynthia R. Denemark, R.Ph.
Deputy Director
Division of Pharmacy
DEHPG/CMCS/CMS

cc:  James G. Scott, Director  Division of Program Operations
     Mai Le-Yuen  Division of Program Operations North Branch
     Sara Albertson  Indiana Office of Medicaid Policy and Planning
**TRANSMITTAL AND NOTICE OF APPROVAL OF STATE PLAN MATERIAL**

**FOR: HEALTH CARE FINANCING ADMINISTRATION**

**TO: REGIONAL ADMINISTRATOR**

**HEALTH CARE FINANCING ADMINISTRATION**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

1. TRANSMITTAL NUMBER: 20-014
2. STATE Indiana
3. PROGRAM IDENTIFICATION: TITLE XIX OF THE SOCIAL SECURITY ACT (MEDICAID)
4. PROPOSED EFFECTIVE DATE: September 1, 2020

5. TYPE OF PLAN MATERIAL (Check One):
   - NEW STATE PLAN
   - AMENDMENT TO BE CONSIDERED AS NEW PLAN
   - AMENDMENT

6. FEDERAL STATUTE/REGULATION CITATION: 42 CFR 447.505

7. FEDERAL BUDGET IMPACT (thousands):
   a. FFY 2020 $0
   b. FFY 2021 $0

8. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT: Attachment 3.19 page 7
   Attachment 3.1-A page 7

9. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION OR ATTACHMENT (If Applicable):
   Attachment 3.19 page 7
   Attachment 3.1-A page 7

10. SUBJECT OF AMENDMENT: This State Plan Amendment makes technical changes to the template utilized in administering the State’s supplemental drug rebate program. In addition, the State is updating the date on an affected page within the state’s State Plan. These changes are being made in order to bring about greater transparency pertaining to the supplemental drug rebate processes and procedures and to fully comply with applicable state requirements for supplemental rebates.

11. GOVERNOR’S REVIEW (Check One):
    - GOVERNOR’S OFFICE REPORTED NO COMMENT
    - COMMENTS OF GOVERNOR’S OFFICE ENCLOSED
    - NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL

   OTHER, AS SPECIFIED:
   Indiana’s Medicaid State Plan does not require the Governor’s review. See Section 7.4 of the State Plan

12. SIGNATURE OF STATE AGENCY OFFICIAL: [Signature]

13. TYPED NAME: Allison Taylor
14. TITLE: Medicaid Director
15. DATE SUBMITTED: September 1, 2020

16. RETURN TO:
    Allison Taylor
    Medicaid Director
    Indiana Office of Medicaid Policy and Planning
    402 West Washington Street, Room W382
    Indianapolis, IN 46204
    ATTN: Sara Albertson, Federal Relations Lead

17. DATE RECEIVED: September 1, 2020
18. DATE APPROVED: September 28, 2020

19. EFFECTIVE DATE OF APPROVED MATERIAL: September 1, 2020

20. SIGNATURE OF REGIONAL OFFICIAL: [Signature]
    Digitally signed by James G. Scott -S
    Date: 2020.10.01 13:25:42 -05’00’

21. TYPED NAME: James G. Scott
22. TITLE: Director, Division of Program Operations

23. REMARKS:
   The state is authorizing Pen & Ink changes to Boxes 8 & 9 to read:
   "Attachment 3.1-A page 7"
12.a. Prescribed Drugs

Provided with limitations.

Reimbursement is available for prescribed drugs subject to the limitations set out in 405 IAC 5. The following are not covered: anorectics or any agent used to promote weight loss; topical minoxidil preparations; fertility enhancement drugs; drugs used to treat sexual or erectile dysfunction, as set forth in section 1927(d)(2)(K) of the Act, unless such drugs are used to treat conditions other than sexual or erectile dysfunction and such uses have been approved by the Food and Drug Administration; drugs prescribed solely or primarily for cosmetic purposes. All over-the-counter and non-legend items are subject to the limitations set out in 405 IAC 5-24.

In accordance with Section 4401 of P.L. 101-508 (Omnibus Budget Reconciliation Act of 1990), Indiana Medicaid will fully participate in the manufacturer rebate program. In doing so, all applicable provisions and restrictions of the legislation, as well as that of any subsequent rules and/or regulations, will be strictly adhered to. Specifically, Indiana Medicaid will reimburse for all rebating manufacturers' (as identified to the agency by CMS) products fully in accordance with the specifications of the legislation. The program will also adhere to all reporting requirements of the legislation.

Supplemental Rebates--The State is in compliance with section 1927 of the Social Security Act. The state will cover drugs of federal rebate participating manufacturers. The state is in compliance with reporting requirements for utilization and restrictions to coverage. Pharmaceutical manufacturers can audit utilization data. The unit rebate amount is confidential and cannot be disclosed for purposes other than rebate invoicing and verification.

The state will be negotiating supplemental rebates in addition to the federal rebates provided for in Title XIX. Rebate agreements between the state and a pharmaceutical manufacturer will be separate from the federal rebates. A rebate agreement between the State and a drug manufacturer for drugs provided to the Medicaid program, submitted to CMS on September 1, 2020 and entitled, State of Indiana Supplemental Rebate agreement, has been authorized by CMS.

Supplemental rebates received by the State in excess of those required under the national drug rebate agreement will be shared with the federal government on the same percentage basis as applied under the national rebate agreement.

All drugs covered by the program, irrespective of prior authorization requirement, will comply with the provisions of the national rebate agreement.